AIO Part I: Interpretable ADMET Prediction for Cyclic Peptides and Macrocycles
Macrocycles and cyclic peptides are increasingly important in beyond-rule-of-five (bRo5) drug discovery, yet their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remain difficult to predict owing to sparse data, complex topology, and environment-dependent conformations. Here, we present AIO (All-in-One), an interpretable multimodal ADMET framework combining topology-preserving molecular segmentation with solvent-aware contrastive pretraining. Across repeated cross-validation, AIO performed strongly across permeability, solubility, unbound fraction, clearance, half-life, bioavailability, and toxicity endpoints, achieving Pearson R = 0.87 for PAMPA permeability and AUROC = 0.91 for bioavailability. Case studies of recently approved macrocyclic and cyclic-peptide drugs showed agreement between predictions and reported pharmacokinetic profiles, while segment-level attribution highlighted molecular regions associated with predicted ADMET bottlenecks. Despite pretraining exclusively on macrocycles, AIO also transferred competitively to the small-molecule PharmaBench dataset. These results establish a promising foundation for interpretable ADMET prediction across diverse molecular modalities in drug discovery.
Authors
- Yue Hong Qian (ORCID: https://orcid.org/0000-0003-1989-7586)
- Sicheng Wen (ORCID: https://orcid.org/0009-0000-9992-9140)
- Shu Wang (ORCID: https://orcid.org/0000-0002-2111-941X)
Institutions
- Viva Biotech (China) (CN)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.64898/2026.11.18.767182
- Primary Topic
- Computational Drug Discovery Methods
- Type
- preprint